NGNE on Nasdaq
Neurogene Inc.
Pharmaceutical preparations company, listed on Nasdaq (NGNE).
Price unavailable
Last updated Oct 18, 2026.
Overview
Compare with Aeglea BioTherapeutics, Corbus Pharmaceuticals or Rallybio, or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Revenue under licensing agreements | $0 | $925.0K |
| Research and development expenses | $75.0M | $60.9M |
| General and administrative expenses | $28.3M | $22.6M |
| Total operating expenses | $103.3M | $83.5M |
| Loss from operations | -$103.3M | -$82.6M |
| Interest income | $11.5M | $8.5M |
| Interest expense | -$5.0K | -$12.0K |
| Other income | $1.7M | $574.0K |
| Other expense | -$230.0K | -$1.6M |
| Net loss | -$90.4M | -$75.1M |
| Net loss per share, basic (in dollars per share) | -$4.24 | -$4.28 |
| Net loss per share, diluted (in dollars per share) | -$4.24 | -$4.28 |
| Weighted-average shares of common stock outstanding, basic (in shares) | 21.3M shares | 17.6M shares |
| Weighted-average shares of common stock outstanding, diluted (in shares) | 21.3M shares | 17.6M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.3
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $103.8M | $136.6M | |
| Short-term investments | $165.2M | $175.8M | |
| Prepaid expenses and other current assets | $2.8M | $3.5M | |
| Total current assets | $271.8M | $315.9M | |
| Property and equipment, net | $12.8M | $15.4M | |
| Operating lease right-of-use assets | $2.6M | $3.0M | |
| Finance lease right-of-use assets | $22.0K | $71.0K | |
| Restricted cash | $339.0K | $339.0K | |
| Other non-current assets | $1.0M | $975.0K | |
| Total assets | $288.6M | $335.7M | |
| Accounts payable | $2.0M | $1.3M | |
| Accrued expenses and other current liabilities | $10.8M | $9.7M | |
| Operating lease liabilities, current | $3.0M | $2.9M | |
| Finance lease liabilities, current | $14.0K | $54.0K | |
| Contingent value rights liability, current | $638.0K | $1.1M | |
| Total current liabilities | $16.4M | $15.2M | |
| Operating lease liabilities, non-current | $6.8M | $9.4M | |
| Finance lease liabilities, non-current | $5.0K | $26.0K | |
| Contingent value rights liability, non-current | $428.0K | $718.0K | |
| Other liabilities | $51.0K | $51.0K | |
| Total liabilities | $23.7M | $25.4M | |
| Preferred stock, $0.000001 par value; 50,000,000 shares authorized as of December 31, 2025 and December 31, 2024; 0 shares issued and outstanding as of December 31, 2025 and December 31, 2024 | $0 | $0 | |
| Common stock, $0.000001 par value; 450,000,000 shares authorized as of December 31, 2025 and December 31, 2024; 15,489,800 and 14,854,725 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | $0 | $0 | |
| Additional paid-in capital | $617.5M | $572.7M | |
| Accumulated deficit | -$352.6M | -$262.3M | |
| Total stockholders' equity | $264.9M | $310.4M | $186.0M |
| Total liabilities and stockholders' equity | $288.6M | $335.7M | |
| Preferred stock, par or stated value per share (in dollars per share) | $0.00 | $0.00 | |
| Preferred stock, shares authorized (in shares) | 50.0M shares | 50.0M shares | |
| Preferred Stock, shares, issued (in shares) | 0 shares | 0 shares | |
| Preferred Stock, shares, outstanding (in shares) | 0 shares | 0 shares | |
| Common stock, par or stated value per share (in dollars per share) | $0.00 | $0.00 | |
| Common stock, shares authorized (in shares) | 450.0M shares | 450.0M shares | |
| Common stock, shares, issued (in shares) | 15.5M shares | 14.9M shares | |
| Common stock, shares, outstanding (in shares) | 15.5M shares | 14.9M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $103.8M | $136.6M | |
| Short-term investments | $165.2M | $175.8M | |
| Prepaid expenses and other current assets | $2.8M | $3.5M | |
| Total current assets | $271.8M | $315.9M | |
| Property and equipment, net | $12.8M | $15.4M | |
| Operating lease right-of-use assets | $2.6M | $3.0M | |
| Finance lease right-of-use assets | $22.0K | $71.0K | |
| Restricted cash | $339.0K | $339.0K | |
| Other non-current assets | $1.0M | $975.0K | |
| Total assets | $288.6M | $335.7M | |
| Accounts payable | $2.0M | $1.3M | |
| Accrued expenses and other current liabilities | $10.8M | $9.7M | |
| Operating lease liabilities, current | $3.0M | $2.9M | |
| Finance lease liabilities, current | $14.0K | $54.0K | |
| Contingent value rights liability, current | $638.0K | $1.1M | |
| Total current liabilities | $16.4M | $15.2M | |
| Operating lease liabilities, non-current | $6.8M | $9.4M | |
| Finance lease liabilities, non-current | $5.0K | $26.0K | |
| Contingent value rights liability, non-current | $428.0K | $718.0K | |
| Other liabilities | $51.0K | $51.0K | |
| Total liabilities | $23.7M | $25.4M | |
| Preferred stock, $0.000001 par value; 50,000,000 shares authorized as of December 31, 2025 and December 31, 2024; 0 shares issued and outstanding as of December 31, 2025 and December 31, 2024 | $0 | $0 | |
| Common stock, $0.000001 par value; 450,000,000 shares authorized as of December 31, 2025 and December 31, 2024; 15,489,800 and 14,854,725 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | $0 | $0 | |
| Additional paid-in capital | $617.5M | $572.7M | |
| Accumulated deficit | -$352.6M | -$262.3M | |
| Total stockholders' equity | $264.9M | $310.4M | $186.0M |
| Total liabilities and stockholders' equity | $288.6M | $335.7M | |
| Preferred stock, par or stated value per share (in dollars per share) | $0.00 | $0.00 | |
| Preferred stock, shares authorized (in shares) | 50.0M shares | 50.0M shares | |
| Preferred Stock, shares, issued (in shares) | 0 shares | 0 shares | |
| Preferred Stock, shares, outstanding (in shares) | 0 shares | 0 shares | |
| Common stock, par or stated value per share (in dollars per share) | $0.00 | $0.00 | |
| Common stock, shares authorized (in shares) | 450.0M shares | 450.0M shares | |
| Common stock, shares, issued (in shares) | 15.5M shares | 14.9M shares | |
| Common stock, shares, outstanding (in shares) | 15.5M shares | 14.9M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$90.4M | -$75.1M |
| Stock-based compensation expense | $14.2M | $8.3M |
| Depreciation and amortization of property and equipment | $3.0M | $3.2M |
| Asset impairment | $120.0K | $91.0K |
| Non-cash operating lease expense | $800.0K | $741.0K |
| Amortization of finance lease right-of-use assets | $49.0K | $52.0K |
| Amortization and accretion of premiums/discounts on held-to-maturity investments | -$4.5M | -$2.4M |
| Change in contingent value rights liability | -$743.0K | $522.0K |
| Gain on lease modification | -$6.0K | $0 |
| Prepaid expenses and other current assets | $952.0K | -$327.0K |
| Other assets | -$58.0K | -$211.0K |
| Accounts payable | $627.0K | -$77.0K |
| Accrued expenses and other liabilities | $1.7M | -$2.8M |
| Operating lease liabilities | -$2.9M | -$2.6M |
| Net cash used in operating activities | -$77.2M | -$70.6M |
| Purchases of property and equipment | -$1.2M | -$808.0K |
| Purchases of held-to-maturity investments | -$269.5M | -$198.5M |
| Proceeds from maturities of held-to-maturity investments | $284.7M | $74.0M |
| Net cash provided by (used in) investing activities | $14.0M | -$125.3M |
| Payment of deferred offering costs related to at-the-market sales agreement | -$241.0K | $0 |
| Proceeds from sale of common stock in at-the-market sales agreement, net of offering costs | $30.4M | $0 |
| Offering costs in connection with pre-closing financing | $0 | -$4.3M |
| Transaction costs related to reverse merger | $0 | -$2.9M |
| Proceeds from the issuance of common stock upon exercise of options | $266.0K | $1.7M |
| Proceeds from private financing, net of offering costs paid | $0 | $189.6M |
| Principal payments on finance leases | -$61.0K | -$52.0K |
| Proceeds from the issuance of common stock under Employee Stock Purchase Plan | $84.0K | $0 |
| Net cash provided by financing activities | $30.4M | $184.1M |
| Net decrease in cash, cash equivalents and restricted cash | -$32.7M | -$11.8M |
| Additions to operating lease right of use assets from new operating lease liabilities | $0 | $60.0K |
| Property and equipment included in accounts payable and accrued expenses | $76.0K | $726.0K |
| Additions to finance lease right of use assets from new finance lease liabilities | $0 | $25.0K |
| Offering costs related to private offering, included in accounts payable and accrued expenses | $0 | $90.0K |
| Cash paid for interest | $5.0K | $12.0K |
| Deferred offering costs reclassified to additional paid-in capital | $50.0K | $0 |
No quarter-by-quarter statement was filed.
Leadership
Who has led Neurogene Inc., and when. Pick a name to see everywhere that person has worked.
Chief executive
Chief financial officer
Chief operating officer
201520202025
- Chief executive officerRachel McMinn Dec 26, 2023 to now11
- Chief executive officerDavid Main Mar 6, 2014 to Aug 9, 201812
- PresidentChristine Mikail Cvijic Dec 26, 2023 to now13
- PresidentDavid Main Mar 6, 2014 to Aug 9, 201812
- Chief financial officerSean Michael Smith Aug 14, 2023 to Aug 14, 202314
- Chief financial officerChristine Mikail Cvijic Dec 26, 2023 to now13
- Chief financial officerRobert Ho Mar 16, 2020 to Feb 2, 202215
- Chief financial officerKamran Alam Mar 6, 2014 to Aug 9, 201816
- Chief operating officerLloyd Mackenzie Mar 13, 2018 to Aug 9, 201817
Board members and other officers (34)
- Chief Commercial OfficerChristina Shafer Apr 20, 2026 to now18
- Chief Medical OfficerJulie Jordan Jan 18, 2024 to now19
- Chief Scientific OfficerStuart Cobb Dec 26, 2023 to now20
- Principal Accounting OfficerSean Michael Smith Mar 3, 2022 to Feb 3, 202321
- Senior Vice PresidentCarl Walkey Feb 2, 2021 to Aug 4, 202222
- Chief Commercial OfficerAbigail Jenkins Jun 15, 2016 to Mar 13, 201823
- Chief Medical OfficerBarbara Troupin Oct 6, 2016 to Mar 13, 201824
- VP, HR and AdministrationShelley McCloskey Dec 23, 2015 to Aug 9, 201825
- VP Technical OperationsLloyd Mackenzie Mar 6, 2014 to Mar 10, 201726
- CMO; Senior VP Clinical Dev.Stephen B. Shrewsbury Mar 6, 2014 to Mar 14, 201627
- Board memberKeith Woods Feb 24, 2026 to now28
- Board memberChristine Mikail Cvijic May 8, 2026 to now29
- Board memberCory S. Freedland Dec 26, 2023 to now30
- Board memberRachel McMinn Dec 26, 2023 to now11
- Board memberRobert Baffi Dec 26, 2023 to now31
- Board memberRohan Palekar Mar 4, 2022 to now32
- Board memberErin Lavelle May 16, 2022 to Jun 9, 202333
- Board memberMartin Babler Sep 10, 2020 to Jun 9, 202334
- Board memberLewis T. Williams Aug 12, 2019 to May 13, 202135
- Board memberSarah B. Noonberg Aug 12, 2019 to now36
- Board memberMeta Cantey Boyd Aug 23, 2019 to Aug 23, 201937
- Board memberKelvin Neu Mar 27, 2017 to Mar 27, 201738
- Board memberFelix Baker May 9, 2017 to Dec 20, 202339
- Board memberJulian Baker May 9, 2017 to Dec 20, 202339
- Board memberL.p. 667 May 9, 2017 to Dec 20, 202339
- Board memberSean P. Nolan Feb 26, 2015 to May 7, 202040
- Board memberDaniel J. Levitt Mar 6, 2014 to May 16, 201841
- Board memberDavid Main Mar 6, 2014 to Aug 9, 201812
- Board memberElaine Jones V. Mar 6, 2014 to Mar 6, 201442
- Board memberGary Bridger Mar 6, 2014 to May 9, 201843
- Board memberRobert Pelzer Mar 6, 2014 to May 9, 201844
- Board memberTodd E. Simpson Mar 6, 2014 to Jun 9, 202345
- General counselDonna Cochener Mar 15, 2022 to Aug 4, 202246
- General counselHolly Vance Oct 20, 2020 to Aug 5, 202147
Former names
Timeline
Filings
306 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 66 major events, 97 insider forms, 55 large holders, 68 other. The latest 20:
- Oct 7, 2026SCHEDULE 13G EDGAR
- Oct 6, 2026SCHEDULE 13G EDGAR
- Oct 2, 20264 EDGAR
- Aug 14, 2026SCHEDULE 13G/A EDGAR
- Aug 14, 2026SCHEDULE 13G EDGAR
- Aug 14, 2026SCHEDULE 13G/A EDGAR
- Aug 11, 202610-Q EDGAR
- Aug 11, 20268-K EDGAR
- Jul 7, 20264 EDGAR
- Jul 2, 2026424B5 EDGAR
- Jul 2, 20264 EDGAR
- Jul 2, 20268-K EDGAR
- Jun 30, 2026424B5 EDGAR
- Jun 29, 20268-K EDGAR
- Jun 16, 20264/A EDGAR
- Jun 16, 20264/A EDGAR
- Jun 16, 20264/A EDGAR
- Jun 16, 20263/A EDGAR
- Jun 8, 20268-K EDGAR
- Jun 4, 20268-K EDGAR
The 306 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last three years, summarized. The full record is on SEC EDGAR.
Insider trades and holders
Large holders
Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 55 such filings since October 2021, the latest 10:
- Oct 7, 2026SCHEDULE 13G
- Oct 6, 2026SCHEDULE 13G
- Aug 14, 2026SCHEDULE 13G/A
- Aug 14, 2026SCHEDULE 13G
- Aug 14, 2026SCHEDULE 13G/A
- Feb 17, 2026SCHEDULE 13G/A
- Dec 15, 2025SCHEDULE 13G
- Nov 14, 2025SCHEDULE 13G/A
- Aug 14, 2025SCHEDULE 13G/A
- Aug 14, 2025SCHEDULE 13G/A
From Forms 4 and Schedules 13D and 13G filed with the SEC.
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| Samsara Biocapital, LLC | 1,717,127 | $54.0M | 4.4% | No change |
| Casdin Capital, LLC | 1,545,361 | $48.6M | 2.4% | +125,000 |
| Redmile Group, LLC | 1,412,199 | $44.4M | 3.0% | −47,400 |
| Rtw Investments, LP | 1,362,456 | $42.8M | 0.4% | No change |
| EcoR1 Capital, LLC | 1,271,342 | $40.0M | 2.0% | No change |
| BlackRock, Inc. | 1,057,983 | $33.3M | 0.0% | +52,913 |
| Baker Bros. Advisors LP | 991,691 | $31.2M | 0.2% | No change |
| Balyasny Asset Management L.P. | 818,706 | $25.7M | 0.0% | +100,317 |
| Trails Edge Capital Partners, LP | 714,885 | $22.5M | 3.6% | −67,902 |
| Toronto Dominion Bank | 681,337 | $21.4M | 0.0% | No change |
| Vanguard Capital Management LLC | 536,525 | $16.9M | 0.0% | +21,798 |
| Jennison Associates LLC | 518,582 | $16.3M | 0.0% | −9,103 |
| Citadel Advisors LLC | 408,982 | $12.9M | 0.0% | +21,951 |
| Great Point Partners LLC | 352,180 | $11.1M | 2.6% | −147,820 |
| ArrowMark Colorado Holdings LLC | 342,453 | $10.8M | 0.4% | −182,343 |
| Fmr LLC | 295,561 | $9.3M | 0.0% | −87,086 |
| Geode Capital Management, LLC | 293,182 | $9.2M | 0.0% | +14,179 |
| State Street Corp | 224,322 | $7.1M | 0.0% | −88,683 |
| Franklin Resources Inc | 204,280 | $6.4M | 0.0% | New |
| Morgan Stanley | 191,724 | $6.0M | 0.0% | −93,515 |
| UBS Group AG | 171,289 | $5.4M | 0.0% | −14,390 |
| Blair William & Co/il | 146,905 | $4.6M | 0.0% | −21,313 |
| Driehaus Capital Management LLC | 143,528 | $4.5M | 0.0% | +110,763 |
| Point72 Asset Management, L.P. | 141,920 | $4.5M | 0.0% | New |
| Moore Capital Management, LP | 141,636 | $4.5M | 0.1% | New |
13F reports cover disclosed long positions in U.S. stocks only.
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1SEC EDGARNeurogene Inc. filings on SEC EDGAR
- 2SEC EDGARNeurogene Inc. filings on SEC EDGAR
- 3SEC EDGARNeurogene Inc. 10-K for fiscal 2025
- 4SEC EDGARNeurogene Inc. 10-K for fiscal 2023
- 5SEC EDGARNeurogene Inc. 10-K for fiscal 2019
- 6SEC EDGARNeurogene Inc. 10-K for fiscal 2020
- 7SEC EDGARNeurogene Inc. 10-K for fiscal 2021
- 8SEC EDGARNeurogene Inc. 10-K for fiscal 2022
- 9SEC EDGARNeurogene Inc. 10-Q for fiscal 2026
- 10SEC EDGARNeurogene Inc. 10-Q for fiscal 2026
- 11
- 12SEC EDGARDavid Main, Chief executive officer
- 13SEC EDGARChristine Mikail Cvijic, President
- 14
- 15SEC EDGARRobert Ho, Chief financial officer
- 16SEC EDGARKamran Alam, Chief financial officer
- 17
- 18
- 19SEC EDGARJulie Jordan, Chief Medical Officer
- 20
- 21
- 22SEC EDGARCarl Walkey, Senior Vice President
- 23
- 24
- 25
- 26
- 27
- 28SEC EDGARKeith Woods, Board member
- 29
- 30SEC EDGARCory S. Freedland, Board member
- 31SEC EDGARRobert Baffi, Board member
- 32SEC EDGARRohan Palekar, Board member
- 33SEC EDGARErin Lavelle, Board member
- 34SEC EDGARMartin Babler, Board member
- 35SEC EDGARLewis T. Williams, Board member
- 36SEC EDGARSarah B. Noonberg, Board member
- 37SEC EDGARMeta Cantey Boyd, Board member
- 38SEC EDGARKelvin Neu, Board member
- 39SEC EDGARFelix Baker, Board member
- 40SEC EDGARSean P. Nolan, Board member
- 41SEC EDGARDaniel J. Levitt, Board member
- 42SEC EDGARElaine Jones V., Board member
- 43SEC EDGARGary Bridger, Board member
- 44SEC EDGARRobert Pelzer, Board member
- 45SEC EDGARTodd E. Simpson, Board member
- 46SEC EDGARDonna Cochener, General counsel
- 47SEC EDGARHolly Vance, General counsel